Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.58 |
| ▸ | MAOB | P27338 | 6/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | TDP2 | O95551 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395799 | 1.00 | MAOA (0.58) | MAOAMAOBCYP2A6HSD17B1MEN1 | |
| SCHEMBL7180348 | 0.89 | MEN1 (0.56) | MAOAMAOBCYP2A6HSD17B1MEN1 | |
| SCHEMBL19686137 | 0.88 | MAOA (0.49) | MAOAMAOBCYP2A6HSD17B1MEN1 | |
| SCHEMBL7584101 | 0.86 | HSD17B1 (0.73) | MAOAMAOBCYP2A6HSD17B1MEN1 | |
| SCHEMBL5211345 | 0.84 | HSD17B1 (0.53) | MAOAMAOBCYP2A6HSD17B1MEN1 | |
| SCHEMBL5204318 | 0.84 | MAOA (0.57) | MAOAMAOBCYP2A6HSD17B1MEN1 | |
| SCHEMBL16821225 | 0.83 | PARP10 (0.50) | MAOAMAOBCYP2A6HSD17B1MEN1 | |
| SCHEMBL27844082 | 0.82 | HSD17B1 (0.51) | MAOAMAOBCYP2A6HSD17B1MEN1 | |
| SCHEMBL27843881 | 0.82 | HSD17B1 (0.51) | MAOAMAOBCYP2A6HSD17B1MEN1 | |
| SCHEMBL21222886 | 0.82 | HSD17B1 (0.68) | MAOAMAOBCYP2A6HSD17B1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4573086-A1 | METHANOGEN INHIBITORS | Agrizeronz Limited Partnership (NZ) | 2025-06-25 | — | — | EP | disclosed |
| CN-119998272-A | Methanogen inhibitors | 阿格里泽伦茨有限合伙公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024039250-A1 | METHANOGEN INHIBITORS | PASTORAL GREENHOUSE GAS RESEARCH LIMITED (NZ) | 2024-02-22 | — | — | WO | disclosed |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11639333-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639333-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639333-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2023-05-02 | — | — | US | disclosed |
| EP-3561876-B1 | DISPLAY | NOVALED GMBH (DE) | 2022-02-16 | — | — | EP | disclosed |
| WO-1996001267-A1 | PHOSPHONIC ACID COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-18 | — | — | WO | disclosed |
| EP-0671172-A1 | AMINO ACID DERIVATIVE | Eisai Co., Ltd. (JP) | 1995-09-13 | — | — | EP | disclosed |
| US-5401735-A | Antibiotics for gramnegative or grampositive bacteria | MERCK & CO., INC. (US) | 1995-03-28 | — | — | US | disclosed |
| WO-1995003700-A1 | BRIDGED BIPHENYL CARBAPENEM ANTIBACTERIAL COMPOUNDS | MERCK & CO., INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| WO-1995003699-A1 | BRIDGED BIPHENYL CARBAPENEM COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| US-5384317-A | Bactericides | MERCK & CO., INC. (US) | 1995-01-24 | — | — | US | disclosed |
| WO-1994028718-A1 | BRIDGED CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MERCK & CO., INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| WO-1994028719-A1 | BRIDGED CARBAPENEM ANTIBACTERIAL COMPOUNDS | MERCK & CO., INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| US-5374630-A | Bridged carbapenem antibacterial compounds | MERCK & CO., INC. (US) | 1994-12-20 | — | — | US | disclosed |
| US-5372993-A | Bridged carbapenem compounds, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 1994-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | MAOA 430/4885MAOB 473/4885CYP2A6 1919/4885 |
| US-11639333-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | MAOA 430/4885MAOB 473/4885CYP2A6 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.